Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.31 is 45% above its 5-year average of -2.37, near the high end of its 5-year range (-3.08–-1.31).
44.49% above its 12-month average of -2.36.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.39.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.31
EARNINGS PER SHARE (EPS) AVG TTM
-2.36
EARNINGS PER SHARE (EPS) AVG 3Y
-2.72
EARNINGS PER SHARE (EPS) AVG 5Y
-2.37
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.49%
CURRENT VS 3Y AVG
+51.79%
CURRENT VS 5Y AVG
+44.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Establishment Labs Holdings Inc.
Market Cap
$1.91B
Earnings Per Share (EPS)
-1.31
TTM Avg
-2.36
3Y Avg
-2.72
5Y Avg
-2.37
Market Cap
$1.90B
Earnings Per Share (EPS)
-7.01
TTM Avg
2.37
3Y Avg
-1.46
5Y Avg
-2.11
Market Cap
$1.89B
Earnings Per Share (EPS)
1.02
TTM Avg
-0.34
3Y Avg
-1.38
5Y Avg
-0.96
Market Cap
$1.89B
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.38
3Y Avg
-0.38
5Y Avg
-0.80
Market Cap
$1.89B
Earnings Per Share (EPS)
-2.02
TTM Avg
-1.35
3Y Avg
-0.63
5Y Avg
-1.69
Market Cap
$1.94B
Earnings Per Share (EPS)
-0.68
TTM Avg
-0.29
3Y Avg
-0.44
5Y Avg
-0.50
Market Cap
$1.88B
Earnings Per Share (EPS)
-2.54
TTM Avg
-3.71
3Y Avg
-3.97
5Y Avg
-3.29
Market Cap
$1.94B
Earnings Per Share (EPS)
-4.24
TTM Avg
-2.98
3Y Avg
-3.43
5Y Avg
-3.06
Market Cap
$1.87B
Earnings Per Share (EPS)
-4.83
TTM Avg
-5.77
3Y Avg
-6.60
5Y Avg
-16.62
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.91B | -1.31 | -2.36 | -2.72 | -2.37 |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | -7.01 | 2.37 | -1.46 | -2.11 |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 1.02 | -0.34 | -1.38 | -0.96 |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | -0.34 | -0.38 | -0.38 | -0.80 |
| Zymeworks Inc. (ZYME)vs › | $1.89B | -2.02 | -1.35 | -0.63 | -1.69 |
| AxoGen, Inc. (AXGN)vs › | $1.94B | -0.68 | -0.29 | -0.44 | -0.50 |
| Immunome, Inc. (IMNM)vs › | $1.88B | -2.54 | -3.71 | -3.97 | -3.29 |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | -4.24 | -2.98 | -3.43 | -3.06 |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | -4.83 | -5.77 | -6.60 | -16.62 |
| Vir Biotechnology, Inc. (VIR)vs › | $1.95B | -1.86 | -3.50 | -1.92 | -1.02 |
Trailing EPS (TTM)
$-1.31
Forward EPS (Est.)
$-1.20
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.72 |
| 2024-12-31 | -3.00 |
| 2023-12-31 | -3.07 |
| 2022-12-31 | -3.08 |
| 2021-12-31 | -1.72 |
| 2020-12-31 | -1.63 |
| 2019-12-31 | -1.86 |
| 2018-12-31 | -1.22 |
| 2017-12-31 | -2.33 |
| 2016-12-31 | -1.20 |
